Skip to main content
. 2024 May 16;9(8):2514–2526. doi: 10.1016/j.ekir.2024.05.007

Figure 4.

Figure 4

Progression to CKD stage 3 of patients the 17q12del compared to HNF1B variants. Progression to CKD is significantly delayed in patients with the 17q12del compared to patients with HNF1B variants (HR: 0.29 [95% CI: 0.19–0.44], P < 0.001). The survival curve was generated using data from children aged ≥ 2 years to dismiss changes in eGFR in early life. The point in time of progression to CKD stage 3 (eGFR < 60 ml/min per 1.73 m2) was entered as the chronological age of each patient. We considered that patients entered the study (baseline) at birth given the fact the HNF1B disease is a congenital nephropathy. The log-rank test for difference in survival yielded a P-value < 0.0001, indicating that the patients with 17q12del and HNF1B variants differed significantly in progression toward CKD stage 3. CI, confidence interval; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; HR, hazard ratio.